Esperion Therapeutics Inc. (ESPR) Trading Up 2.7%
Esperion Therapeutics Inc. (NASDAQ:ESPR) shares were up 2.7% during mid-day trading on Monday . The company traded as high as $11.69 and last traded at $11.52, with a volume of 214,925 shares traded. The stock had previously closed at $11.22.
A number of research analysts recently issued reports on ESPR shares. Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday, August 9th. Lake Street Capital dropped their price target on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, June 29th. Vetr raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 price objective for the company in a research report on Monday, August 1st. WallachBeth Capital cut Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price objective for the company. in a research report on Tuesday, July 5th. Finally, JMP Securities reaffirmed a “buy” rating and set a $67.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.40.
The stock’s market capitalization is $257.97 million. The stock has a 50-day moving average of $10.96 and a 200 day moving average of $14.40.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/esperion-therapeutics-inc-espr-trading-up-2-7.html
Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. During the same period last year, the company earned ($0.55) earnings per share. Equities analysts predict that Esperion Therapeutics Inc. will post ($3.37) EPS for the current year.
In other news, Director Mark E. Mcgovern bought 5,000 shares of the business’s stock in a transaction on Wednesday, July 6th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the director now directly owns 600 shares of the company’s stock, valued at approximately $6,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 35.40% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in ESPR. BlackRock Institutional Trust Company N.A. increased its stake in Esperion Therapeutics by 1.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 330,950 shares of the biopharmaceutical company’s stock worth $5,596,000 after buying an additional 4,471 shares during the period. Rhenman & Partners Asset Management AB increased its stake in Esperion Therapeutics by 50.0% in the first quarter. Rhenman & Partners Asset Management AB now owns 150,000 shares of the biopharmaceutical company’s stock worth $2,537,000 after buying an additional 50,000 shares during the period. Bellevue Group AG purchased a new stake in Esperion Therapeutics during the first quarter worth $676,000. Geode Capital Management LLC increased its stake in Esperion Therapeutics by 17.8% in the first quarter. Geode Capital Management LLC now owns 107,392 shares of the biopharmaceutical company’s stock worth $1,815,000 after buying an additional 16,208 shares during the period. Finally, A.R.T. Advisors LLC increased its stake in Esperion Therapeutics by 93.6% in the first quarter. A.R.T. Advisors LLC now owns 200,858 shares of the biopharmaceutical company’s stock worth $3,396,000 after buying an additional 97,112 shares during the period. Hedge funds and other institutional investors own 65.22% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Ratings for Esperion Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.